Phase I Trial Evaluating Genetically Modified Autologous T Cells Expressing a T-Cell Receptor Recognizing a Cancer/Germline Antigen in Patients Having Solid Tumors With Emphasis on NSCLC or HNSCC
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2018
At a glance
- Drugs IMA-201 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ACTengine
- Sponsors Immatics US
- 15 Jun 2018 Planned End Date changed from 31 Dec 2033 to 1 Dec 2033.
- 15 Jun 2018 Planned primary completion date changed from 31 Dec 2018 to 1 Dec 2019.
- 26 Sep 2017 Status changed from not yet recruiting to recruiting.